Showing results (231-240 of 277) with videos related to
Sort By:
Pageof 28
Ultrasonography (Seoul, Korea)|May 26, 2020
The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using SonazoidJae Young Lee, Yasunori Minami, Byung Ihn Choi, et al.Journal of Gastroenterology|October 9, 2023
New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver diseaseHaruki Uojima, Kadzuki Nakabayashi, Kazumi Yamasaki, et al.Cancer Medicine|August 11, 2023
Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumabKazuhiro Nouso, Shohei Shiota, Rio Fujita, et al.Cancer Reports (Hoboken, N.J.)|June 11, 2021
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experienceAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 29, 2026
Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and TremelimumabKazuhiro Nouso, Akiko Wakuta, Shohei Shiota, et al.Radiology|August 20, 2024
US Markers and Necroinflammation, Steatosis, and Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease: The iLEAD StudyKatsutoshi Sugimoto, Fuminori Moriyasu, Marco Dioguardi Burgio, et al.European Journal of Gastroenterology & Hepatology|February 16, 2022
Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2021
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Cancer Medicine|April 20, 2022
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Medicine|December 9, 2022
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation studyToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Pageof 28